Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants.

The retroviral proteases (PRs) have a structural feature called the flap, which consists of a short anti-parallel beta-sheet with a turn. The flap extends over the substrate binding cleft and must be flexible to allow entry and exit of the polypeptide substrates and products. We analyzed the sequence requirements of the amino acids within the flap region (positions 46-56) of the HIV-1 PR. The phenotypes of 131 substitution mutants were determined using a bacterial expression system. Four of the mutant PRs with mutations in different regions of the flap were selected for kinetic analysis. Our phenotypic analysis, considered in the context of published structures of the HIV-1 PR with a bound substrate analogs, shows that: (i) Met-46 and Phe-53 participate in hydrophobic interactions on the solvent-exposed face of the flap; (ii) Ile-47, Ile-54, and Val-56 participate in hydrophobic interactions on the inner face of the flap; (iii) Ile-50 has hydrophobic interactions at the distance of both the delta and gamma carbons; (iv) the three glycine residues in the beta-turn of the flap are virtually intolerant of substitutions. Among these mutant PRs, we have identified changes in both kcat and Km. These results establish the nature of the side chain requirements at each position in the flap and document a role for the flap in both substrate binding and catalysis.

[1]  A Wlodawer,et al.  Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. , 1992, The Journal of biological chemistry.

[2]  M. Brann,et al.  Structure of a G-protein-coupling Domain of a Muscarinic Receptor Predicted by Random Saturation Mutagenesis (*) , 1996, The Journal of Biological Chemistry.

[3]  A. Wlodawer,et al.  Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites. , 1992, Biochemistry.

[4]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[5]  C. Hutchison,et al.  Complete mutagenesis of protein coding domains. , 1991, Methods in enzymology.

[6]  M. Simon,et al.  Mutational analysis of G protein α subunit Goα expressed in Escherichia coli , 1993 .

[7]  L. Jagodzinski,et al.  Complete nucleotide sequences of functional clones of the AIDS virus. , 1987, AIDS research and human retroviruses.

[8]  S. Kent,et al.  Catalytic contribution of flap-substrate hydrogen bonds in "HIV-1 protease" explored by chemical synthesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M Yarus,et al.  tRNA structure and ribosomal function. I. tRNA nucleotide 27-43 mutations enhance first position wobble. , 1994, Journal of molecular biology.

[10]  S Foundling,et al.  Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. , 1995, Biochemistry.

[11]  L. Everitt,et al.  Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Kuo,et al.  Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration. , 1992, The Journal of biological chemistry.

[13]  A Wlodawer,et al.  Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. , 1991, Biochemistry.

[14]  R. Myers,et al.  In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease , 1995, Journal of virology.

[15]  B. Katzenellenbogen,et al.  Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. , 1993, The Journal of biological chemistry.

[16]  R. Maurer,et al.  In Vivo Mutational Analysis of the DNA Binding Domain of the Tissue-specific Transcription Factor, Pit-1 (*) , 1995, The Journal of Biological Chemistry.

[17]  D Norbeck,et al.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.

[18]  T. L. Blundell,et al.  Structural evidence for gene duplication in the evolution of the acid proteases , 1978, Nature.

[19]  Maria Miller,et al.  Crystal structure of a retroviral protease proves relationship to aspartic protease family , 1989, Nature.

[20]  C. Hutchison,et al.  A complete library of point substitution mutations in the glucocorticoid response element of mouse mammary tumor virus. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Debouck,et al.  Inhibitor binding to the Phe53Trp mutant of HIV-1 protease promotes conformational changes detectable by spectrofluorometry. , 1993, Biochemistry.

[23]  J. Condra,et al.  Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. , 1994, Biochemistry.

[24]  T. Koyama,et al.  Conversion from Farnesyl Diphosphate Synthase to Geranylgeranyl Diphosphate Synthase by Random Chemical Mutagenesis (*) , 1996, The Journal of Biological Chemistry.

[25]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[26]  Jack R. Collins,et al.  Flap opening in HIV-1 protease simulated by ‘activated’ molecular dynamics , 1995, Nature Structural Biology.

[27]  H. Nitschko,et al.  Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. , 1995, AIDS research and human retroviruses.

[28]  A. Anderson.  Japanese psychiatry: Abuse for visiting scientists , 1985, Nature.

[29]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[30]  A Wlodawer,et al.  Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. , 1991, Biochemistry.

[31]  Marianne Manchester,et al.  Complete mutagenesis of the HIV-1 protease , 1989, Nature.

[32]  C. Hutchison,et al.  Identification of temperature-sensitive mutants of the human immunodeficiency virus type 1 protease through saturation mutagenesis. Amino acid side chain requirements for temperature sensitivity. , 1994, The Journal of biological chemistry.

[33]  M G Grütter,et al.  Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. , 1995, Structure.

[34]  A. Kaplan,et al.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions , 1994, Journal of virology.

[35]  C. Hutchison,et al.  Expression and processing of the AIDS virus reverse transcriptase in Escherichia coli. , 1987, Science.

[36]  S. L. Le Grice,et al.  Processing protease and reverse transcriptase from human immunodeficiency virus type I polyprotein in Escherichia coli , 1988, Journal of virology.

[37]  C. Hutchison,et al.  Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases , 1989, Journal of virology.

[38]  J. Schroeder,et al.  Identification of Strong Modifications in Cation Selectivity in an Arabidopsis Inward Rectifying Potassium Channel by Mutant Selection in Yeast (*) , 1995, The Journal of Biological Chemistry.

[39]  C Cruz,et al.  Genetic studies of the lac repressor. XIV. Analysis of 4000 altered Escherichia coli lac repressors reveals essential and non-essential residues, as well as "spacers" which do not require a specific sequence. , 1994, Journal of molecular biology.

[40]  C. Debouck,et al.  Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[41]  I B Duncan,et al.  Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. , 1995, Virology.

[42]  D. Davies,et al.  The structure and function of the aspartic proteinases. , 1990 .

[43]  S. Gulnik,et al.  In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine , 1993, Antimicrobial Agents and Chemotherapy.

[44]  Thomas A. Kunkel,et al.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[45]  John P. Overington,et al.  X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes , 1989, Nature.

[46]  Dale J. Kempf,et al.  Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease , 1994 .

[47]  M. Jaskólski,et al.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.

[48]  C. Cameron,et al.  Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. , 1994, The Journal of biological chemistry.

[49]  S. Pettit,et al.  The specificity of the HIV-1 protease , 1993 .

[50]  A Wlodawer,et al.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.

[51]  J. Morrison,et al.  [17] The kinetics of reversible tight-binding inhibition , 1979 .

[52]  Baoguang Zhao,et al.  Three-dimensional structure of a simian immunodeficiency virus protease/inhibitor complex. Implications for the design of human immunodeficiency virus type 1 and 2 protease inhibitors. , 1993, Biochemistry.